John Tchelingerian
Président chez Antion Biosciences SA
Profil
John Tchelingerian is the founder of Neurotech Pharmaceuticals, Inc. (United States),Keyobs SA. He currently holds the position of Chairman at Antion Biosciences SA, Chairman-Supervisory Board at Pan Cancer T, and Director at BioWin ASBL.
Previously, he served as President, Chief Executive Officer & Director at PROMETHERA Biosciences SA from 2015 to 2020.
He was also Chairman at Tc Land Expression SA in 2012 and held the position of Principal at Diatos SA. Additionally, he served as a Director at Endotis Pharma SARL.
Dr. Tchelingerian holds a doctorate degree from Université Pierre et Marie Curie.
Postes actifs de John Tchelingerian
| Sociétés | Poste | Début |
|---|---|---|
BioWin ASBL
 BioWin ASBL Miscellaneous Commercial ServicesCommercial Services BioWin ASBL operates as non-profit organization, with interest in the health biotechnology sector. With its member, the firm provides support for the funding in the research and development of biomarkers, nano medicine, drug delivery system, novel therapies, medical devices, and information technology applied to human health. The company is headquartered in Gosselies, Belgium. | Directeur/Membre du Conseil | - |
Pan Cancer T
 Pan Cancer T BiotechnologyHealth Technology Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023. | Président | - |
Antion Biosciences SA
 Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | Président | 09/08/2023 |
Anciens postes connus de John Tchelingerian
| Sociétés | Poste | Fin |
|---|---|---|
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Directeur Général | 27/08/2020 |
Diatos SA
 Diatos SA Pharmaceuticals: MajorHealth Technology Diatos SA develops innovative therapies for the treatment of cancer. The firm leverages its peptide-based, intracellular drug delivery & tumor targeting technologies to improve the properties of existing therapeutics. Its products include DaunoXome, DTS-301 and DTS-108. The company was founded in 1999 and headquartered in Paris, France. | Corporate Officer/Principal | - |
Keyobs SA
 Keyobs SA Engineering & ConstructionIndustrial Services Keyobs SA specializes in geographic information system and remote sensing technologies. It offers maps and spatial analyses, cartographic documents and solutions, map making, structuration and management of databases, refugee camp modelling, epidemiological analyses, and geological and mining services. In addition, the company also develops personalized web-mapping solutions to manage and exchange geographical data through the internet. Keyobs SA was founded in 2001 and is headquartered in Herstal, Belgium. | Fondateur | - |
Neurotech Pharmaceuticals, Inc. (United States)
 Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI. | Fondateur | - |
Tc Land Expression SA
 Tc Land Expression SA Miscellaneous Commercial ServicesCommercial Services Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France. | Directeur Général | - |
Formation de John Tchelingerian
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Diatos SA
Diatos SA Pharmaceuticals: MajorHealth Technology Diatos SA develops innovative therapies for the treatment of cancer. The firm leverages its peptide-based, intracellular drug delivery & tumor targeting technologies to improve the properties of existing therapeutics. Its products include DaunoXome, DTS-301 and DTS-108. The company was founded in 1999 and headquartered in Paris, France. | Health Technology |
Neurotech Pharmaceuticals, Inc. (United States)
Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI. | Health Technology |
Endotis Pharma SARL
 Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | Health Technology |
| Université Pierre et Marie Curie | Consumer Services |
Tc Land Expression SA
Tc Land Expression SA Miscellaneous Commercial ServicesCommercial Services Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France. | Commercial Services |
Keyobs SA
Keyobs SA Engineering & ConstructionIndustrial Services Keyobs SA specializes in geographic information system and remote sensing technologies. It offers maps and spatial analyses, cartographic documents and solutions, map making, structuration and management of databases, refugee camp modelling, epidemiological analyses, and geological and mining services. In addition, the company also develops personalized web-mapping solutions to manage and exchange geographical data through the internet. Keyobs SA was founded in 2001 and is headquartered in Herstal, Belgium. | Industrial Services |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
BioWin ASBL
BioWin ASBL Miscellaneous Commercial ServicesCommercial Services BioWin ASBL operates as non-profit organization, with interest in the health biotechnology sector. With its member, the firm provides support for the funding in the research and development of biomarkers, nano medicine, drug delivery system, novel therapies, medical devices, and information technology applied to human health. The company is headquartered in Gosselies, Belgium. | Commercial Services |
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | Health Technology |
Pan Cancer T
Pan Cancer T BiotechnologyHealth Technology Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023. | Health Technology |